Thought-provoking interviews with industry experts on topics critical to the diagnosis, treatment, and prevention of progressive eye health.
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
October 6th 2022Tom Ruggia, President and CEO of Samsara Vision, provides updates on the lead asset for late-state age-related macular degeneration: Smaller-incision, new generation, implantable miniature telescope (SING IMT).
RGX-314 demonstrates DRSS improvements in patients with DME, NPDR
July 15th 2022At ASRS in New York City, Charles Wykoff, MD, presented a talk entitled, “Suprachoroidal Delivery of RGX-314 Gene Therapy for Diabetic Retinopathy: Phase II ALTITUDE Study.” The trial demonstrated large improvements for patients with diabetic macular edema (DME) and non-proliferative diabetic retinopathy (NPDR), with notable improvements according to the Diabetic Retinopathy Severity Scale (DRSS).
DME: Faricimab remains durable, effective in 2-year results of YOSEMITE and RHINE trials
July 14th 2022At ASRS in New York City, New York, David Eichenbaum, MD, presented “Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-year Results on the Phase 3 YOSEMITE and RHINE Trials.”
The relationship between outer retinal integrity, subretinal fluid may affect treatment outcomes
July 14th 2022At ASRS in New York City, New York, Justis Ehlers, MD, presented a talk entitled, “Higher Order OCT Feature Assessments of the Impact of Fluid Dynamics on Visual Acuity in Neovascular AMD in a Phase III Clinical Trial: The Importance of Outer Retinal Integrity.” Here he discusses the findings.